This information was published on 2023-09-21T02:09:30 for IP Right Filed Published.
| Field | Value |
| (210) | 2390163 (IR 1751881) |
| (220) |
20 Jul 2023
|
| (300) |
US, 02 Feb 2023, 97777750
|
| (511) (510) |
Class 5
Pharmaceutical preparations and substances for the treatment of human diseases, animal diseases, cancer, autoimmune diseases, and infectious diseases for scientific, clinical, medicinal, and therapeutic purposes; pharmaceutical preparations and substances for the prevention of human diseases, animal diseases, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases, animal diseases, cancer, autoimmune diseases, and infectious diseases; biological preparations for medical purposes, namely, in the fields of immunotherapy, and immuno-oncology; anti-infectives for medical use for the treatment of human diseases, animal diseases, autoimmune diseases, and infectious diseases. Class 42 Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, infectious diseases, human diseases, animal diseases; product development in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, infectious diseases, human diseases and animal diseases. Class 44 Medical services; medical information; providing medical information in the fields of immunotherapy via a website; providing medical information in the fields of oncology, cancer, immune-oncology, autoimmune diseases, infectious diseases, human diseases, and animal diseases via a website; providing information relating to pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, infectious diseases, human diseases and animal diseases. |
| (540) | NKIND |
| (550) | Word |
| (730) |
ImmunityBio, Inc.
|
Find out more about publications on the About page.